{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T05:08:08Z","timestamp":1780376888692,"version":"3.54.1"},"reference-count":13,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"DOI":"10.3389\/fmed.2026.1744216","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T04:28:19Z","timestamp":1780374499000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Making the case for azathioprine, methotrexate, and cyclosporine in active vitiligo management"],"prefix":"10.3389","volume":"13","author":[{"given":"Yan","family":"Valle","sequence":"first","affiliation":[{"name":"Vitiligo Research Foundation","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Sigova","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Studies Guglielmo Marconi","place":["Rome, Italy"]},{"name":"Department of Neonatology, Faculty of Continued Medical Education, Pirogov Russian National Research Medical University","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Borodina","sequence":"additional","affiliation":[{"name":"Russian Children's Clinical Hospital, Pirogov Russian National Research Medical University","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyailya N.","family":"Kayumova","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Communicable Diseases, Ministry of Health, I. M. Sechenov First Moscow State Medical University","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliya I.","family":"Almakaeva","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Communicable Diseases, Ministry of Health, I. M. Sechenov First Moscow State Medical University","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir B.","family":"Pinegin","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Communicable Diseases, Ministry of Health, I. M. Sechenov First Moscow State Medical University","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin","family":"Lomonosov","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Communicable Diseases, Ministry of Health, I. M. Sechenov First Moscow State Medical University","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2023.2162","article-title":"Incidence and prevalence of diagnosed vitiligo according to race and ethnicity, age, and sex in the US","author":"Mastacouris","year":"2023","journal-title":"JAMA Dermatol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1001\/jamadermatol.2023.2787","article-title":"Mental health and psychosocial quality-of-life burden among patients with vitiligo: findings from the global VALIANT study","volume":"159","author":"Bibeau","year":"2023","journal-title":"JAMA Dermatol"},{"key":"B3","article-title":"The efficacy of low-dose oral corticosteroids in the treatment of vitiligo patient","author":"Banerjee","year":"2003","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"591","DOI":"10.4103\/ijd.ijd_865_22","article-title":"Comparison of oral azathioprine and oral mini pulse steroid in the treatment of vitiligo: an open-label randomized controlled trial","volume":"68","author":"Jawade","year":"2023","journal-title":"Indian J Dermatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.4103\/idoj.idoj_669_24","article-title":"Value of azathioprine in controlling vitiligo Activity","author":"El-Husseiny","year":"2025","journal-title":"Indian Dermatol Online J"},{"key":"B6","article-title":"Low-dose methotrexate for vitiligo","author":"Garza-Mayers","year":"2017","journal-title":"J Drugs Dermatol"},{"key":"B7","article-title":"Methotrexate gel either alone or combined with narrow band ultraviolet B or excimer light for the treatment of vitiligo","author":"Gharib","year":"2023","journal-title":"J Clin Aesthet Dermatol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e15033","DOI":"10.1111\/dth.15033","article-title":"Oral cyclosporine is effective in stabilizing active vitiligo: Results of a randomized controlled trial","volume":"34","author":"Mehta","year":"2021","journal-title":"Dermatol Ther"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.17816\/dv625411","author":"Nikulina","year":"2024","journal-title":"Russ J Skin Venereal Dis"},{"key":"B10","unstructured":"Geneva: World Health Organization; 2023"},{"key":"B11","unstructured":"Opzelura (ruxolitinib) cream pricing"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"204","DOI":"10.4103\/ijpd.ijpd_84_21","article-title":"A Comprehensive Review of Immunosuppressive Drugs in Pediatric Dermatoses: Part II \u2013 Methotrexate and Mycophenolate Mofetil","volume":"23","author":"Bose","year":"2022","journal-title":"Indian J Paediatr Dermatol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1744216\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T04:28:20Z","timestamp":1780374500000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1744216\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":13,"alternative-id":["10.3389\/fmed.2026.1744216"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1744216","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]},"article-number":"1744216"}}